Clinicopathological characteristics of patients with UBC in the SYSMH cohort and the SYSUCC cohort
| Variables | SYSMH cohort (cohort A) (n=177) | SYSUCC cohort (cohort B) (n=160) |
| Age (years; median (range)) | 63 (1–90) | 60 (36–90) |
| Sex (n (%)) | ||
| Male | 150 (84.7) | 140 (87.5) |
| Female | 27 (15.3) | 20 (12.5) |
| Tumor size | ||
| ≤3 cm | 63 (35.6) | 63 (39.4) |
| >3 cm | 114 (64.4) | 97 (60.6) |
| Multifocality | ||
| Unifocal | 97 (54.8) | 82 (51.3) |
| Multifocal | 80 (45.2) | 78 (48.7) |
| Tumor stage | ||
| Ta–T1 | 88 (49.7) | 29 (18.1) |
| T2–T4 | 89 (50.3) | 131 (81.9) |
| Nodal status | ||
| N0 | 153 (86.4) | 131 (81.9) |
| N1–N2 | 24 (13.6) | 29 (18.1) |
| Histological grade | ||
| Low | 73 (41.3) | 47 (29.4) |
| High | 104 (58.7) | 113 (70.6) |
| NNMT+CAFs | ||
| Low | 90 (50.8) | 81 (50.6) |
| High | 87 (49.2) | 79 (49.4) |
| No. of deaths | 37 (20.9) | 68 (40.5) |
| Overall survival (OS), months (median, range) | 44 (4–89) | 47 (1–159) |
CAFs, cancer-associated fibroblasts; NNMT, nicotinamide N-methyltransferase; SYSMH, Sun Yat-sen Memorial Hospital; SYSUCC, Sun Yat-sen University Cancer Center; UBC, urothelial bladder cancer.